US: Trump’s Efforts to Rein In Drug Prices Face Setbacks - - PressFrom - US
  •   
  •   
  •   

USTrump’s Efforts to Rein In Drug Prices Face Setbacks

02:15  12 july  2019
02:15  12 july  2019 Source:   nytimes.com

Judge strikes down rule requiring drug ads to reveal prices

Judge strikes down rule requiring drug ads to reveal prices WASHINGTON (AP) — A federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads. 

President Trump will lay out a plan this month to make good on his promise to lower prescription prices . Drug companies are ready to resist. Big Pharma is pouring money into a lobbying campaign to thwart any serious efforts to rein in prescription drug prices ahead of a presidential speech this

Trump targets big pharma with new drug price executive order. Former Celgene CEO Bob Hugin on President Trump ' s efforts to rein in drug prices Nations like Greece and Portugal have notoriously low prices and forcing drugmakers to offer their products in the U.S. at those levels would erode profit

Trump’s Efforts to Rein In Drug Prices Face Setbacks© Doug Mills/The New York Times President Trump signing an executive order on improving medical care for Americans who have kidney disease on Wednesday.

President Trump’s plan to lower prescription drug prices hit two major obstacles this week. He killed a proposal on Thursday that would have reduced out-of-pocket costs for older consumers out of concern that it would raise premiums heading into his re-election campaign. And a federal judge threw out a new requirement that drug companies disclose their prices in television ads.

Administration officials rushed to assure the public that the double setback did not reflect failure on one of the president’s signature issues, one that has fueled public outrage and drawn the attention of both parties.

White House pulls the plug on proposed drug rebate overhaul

White House pulls the plug on proposed drug rebate overhaul The White House abandoned a push to end rebates paid to middlemen who negotiate drug prices on behalf of health insurers, a move that could turn scrutiny back on how drugmakers themselves set prices. President Donald Trump has made lowering prescription drug costs a top priority of his administration, and ending rebates was seen as a vital part of that effort. The reversal caused investors to recalibrate their expectations. After mostly languishing this year, shares of companies that operate large pharmacy-benefit managers rallied, with shares of CVS Health and UnitedHealth Group rising sharply.

The bipartisan efforts by states come as President Trump and his administration put pressure on drug companies to freeze prices and reduce out-of-pocket Reining in drug costs is a top priority for state officials who run Medicaid, the health program that serves more than 70 million low-income people.

Obviously, drug manufacturers are eager to have their drugs appear on these lists and they pay kickbacks to the PBMs. (They call them “rebates.”) This drives up the total costs and the net effect is your prescriptions cost more. The administration is trying to change the rules via Health and Human

He has hinted that he is focusing in on a more audacious proposal, especially from a Republican president. It would tie some drug prices to those set by European governments, an idea that is tantamount to price controls and opposed by members of his own party. Yet Mr. Trump is said to be particularly taken with the idea because it fits with his “America First” approach.

“The American senior and the American patient have been too long been asked to overpay for drugs to subsidize the socialist systems of Europe,” said Alex M. Azar II, the secretary of health and human services. “It’s time for the American patient to stop propping up the socialism of Europe.”

Sign Up For the Morning Briefing Newsletter

The administration and leading members of Congress have also been discussing legislative proposals, including negotiating directly with companies to set price caps on some drugs, and placing a limit on out-of-pocket spending by Medicare beneficiaries. The government efforts pack a broad populist appeal, particularly with older Americans, who remain one of the nation’s most reliable voting blocs.

Bernie Sanders brushes off likability concerns, maintains focus on platform

Bernie Sanders brushes off likability concerns, maintains focus on platform Sen. Bernie Sanders pushed back against the notion that he has not shared enough about his personal life and family during his two presidential runs.

Drug prices are still increasing. While growth in spending on drugs has slowed in recent years, total Most notable among them were efforts at transparency and simplification: eliminating some rebates As Trump briefly acknowledged, if the country really wanted to rein in the pharmaceutical industry

The Trump administration concluded that Medicare was paying hospitals much more than they But drug makers have increased prices on hundreds of products this month, provoking an angry Charles E. Grassley, Republican of Iowa, said they were hoping to work with Mr. Trump to rein in drug prices .

But many of these plans face stiff opposition from the powerful pharmaceutical and insurance lobbies, which have already taken the administration to court on some issues.

Another of Mr. Trump’s goals — ending so-called surprise medical billing, when patients receive medical care, then get unexpected bills from providers who are not in their insurance network — is also on shaky ground. Doctors and hospitals are pushing back fiercely against legislation moving through Congress.

During a question-and-answer session with reporters, Mr. Azar tried to rebuff impressions that the administration’s efforts to tackle drug prices were flailing.

A former Eli Lilly executive, Mr. Azar had been the architect of the proposal abandoned on Thursday that would have eliminated drug rebates that companies pay pharmacy benefit managers, like CVS Caremark or Express Scripts. Some argue that the hidden rebates help to drive up prices because the discounts are not passed on to consumers.

Philippines slam UN Human Rights Council decision to probe drug war

Philippines slam UN Human Rights Council decision to probe drug war The United Nations Human Rights Council has voted to investigate the thousands of killings in the Philippines tied to President Rodrigo Duterte's ongoing war on drugs, a move which the country's foreign minister quickly denounced as unjust. The resolution was put forward by Iceland at the Human Rights Council in Geneva Thursday and passed with 18 votes. Fifteen countries abstained, and 14 voted against it. International human rights groups and UN bodies have previously expressed concerns about the Duterte administration's scorched earth-approach in its efforts to eradicate the methamphetamine trade.

Trump ’ s effort to plant Moore on the Fed board was another in a string of attempts to use executive authority and the bully pulpit in ways that could goose But Trump has faced criticism for focusing on short-term economic stimulus, including big tax cuts and government spending increases, to heat the

Drug prices in the United States are the highest in the world; many countries with centralized health care systems have successfully negotiated lower prices from pharmaceutical companies. Trump said on Friday he would rein in this game-playing, saying “our patent system will reward innovation

His briefing also seemed a calculated attempt not only to convince the public that Mr. Trump was making progress, but also that he had strong ideas for improving the nation’s health care system over all.

Democrats successfully used Mr. Trump’s attacks on the Affordable Care Act in last year’s midterm elections, and are gearing up to do so again in 2020, focusing on the administration’s decision to join forces in a court case with several states seeking to invalidate it.

Mr. Trump’s decision to withdraw the rebate rule represented a rare loss for the drug industry, which has long cultivated a friendly relationship with Republicans. It had strongly backed the rebate measure, in its attempt to blame pharmacy benefit managers for rising prices.

The stocks of several major drugmakers, such as Merck, Eli Lilly and Pfizer, closed lower on Thursday, while the stocks of large insurers and pharmacy benefit managers were up.

“Now that the administration has abandoned what it was going to do to address the middlemen, pharma is the only one sort of standing there with a target on its back,” said Rob Smith, a director at Capital Alpha Partners. “I don’t think they’ve ever been in a worse situation.”

Russia launches space telescope

Russia launches space telescope Russia launched a space telescope Saturday from the cosmodrome in Baikonur, Kazakhstan, a joint project with Germany intended to replace one it lost in January. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.getMedianetNativeAds(true); }); Video posted on the website of the Roskosmos, the Russian space agency, showed a Proton-M rocket carrying the Spektr-RG taking off from the launch pad at Baikonur. The launch was originally scheduled for June 21 but was postponed twice because of a battery problem.

WASHINGTON — The pharmaceutical industry, pilloried by President Trump for the last two years, is war-gaming for the possibility that its worst fear is realized: that Democrats, if they flip control of the House, find common ground with the president to rein in drug prices .

WASHINGTON — President Trump will lay out on Friday a broad strategy to reduce prescription drug prices , but in a break from one of his most popular campaign promises, he Congressional Democrats said they would like to work with Mr. Trump on plans to rein in drug costs, but they predicted that his

In a statement, the Pharmaceutical Research and Manufacturers of America, the lead trade group, called the president’s decision to drop the rebate rule disappointing.

Mr. Azar contended that Congress might have better tools to rein in drug prices, and for now, the legislative package that is still being honed in Congress may offer Mr. Trump and Republicans a rallying point on the campaign trail. Mr. Azar and Joe Grogan, the director of the White House Domestic Policy Council, met on Capitol Hill on Tuesday with Republican lawmakers to discuss some of the proposals.

Last Friday, Mr. Trump alluded to an executive order that would require pharmaceutical companies to offer the federal government among the lowest prices in the world. And on Wednesday in announcing a kidney-care initiative, he mentioned drug prices again, saying, “I think we have some very big moments coming up very shortly.”

What Mr. Trump meant was not immediately clear. He may have been referring to a more modest plan already under review, which would apply only to drugs administered in doctors’ offices or hospitals.

But his remarks hewed to a familiar theme: The president has long railed against what he describes as “global freeloading” — the fact that other countries negotiate far lower prices for drugs than what pharmaceutical companies charge in the United States.

Seven arrested, two guns seized in Meriden drug bust

Seven arrested, two guns seized in Meriden drug bust MERIDEN — Seven people were arrested Monday and charged with alleged drug and conduct-related offenses as police seized “a considerable amount of drugs” and two handguns in an early morning raids. Meriden police from the crime supression, detective and SWAT units, as well as the Cheshire / Wallingford Regional SWAT Team, executed a search and seizure warrant at approximately 5 a.m. Monday, Lt. John Mennone said on Facebook. Detectives “retrieved two (2) handguns along with a significant amount of ammunition, $ 4.937.00 in cash and a considerable amount of drugs and drug paraphernalia,” Mennone said.

WASHINGTON — In his effort to bring down prescription drug prices , President Trump is testing the limits of a law that prohibits the government from interfering in negotiations between drug manufacturers and insurance companies that provide drug coverage to more than 42 million people

Trump vowed to take on prescription drug prices , pursue an end to the HIV epidemic and boost funding for childhood cancers. The most likely ground for bipartisanship will be the issue of drug prices , where Democrats are as eager as the president to do something to rein in prices that are

Debate Over the Rebate Rule

Mr. Azar has been the leading champion of trying to eliminate rebates as a centerpiece of the administration’s plans to offer relief to consumers from rising drug costs. He was still promoting it as recently as June, to showcase how the market for drugs is broken.

But fiscal conservatives at the White House had long balked at the potential cost, and others had worried about angering Medicare beneficiaries in an election year.

Though it would have lowered out-of-pocket costs for older Americans with expensive drugs, the rule was expected to raise drug-plan premiums for all Medicare beneficiaries. In May, the nonpartisan Congressional Budget Office concluded that the rule, if adopted, would cost taxpayers $177 billion within 10 years.

The initiative was intended to eliminate after-the-fact rebates that drugmakers pay to the private companies that operate Medicare’s Part D drug plans, and instead required that any discounts be passed to consumers at the pharmacy counter.

Medicare beneficiaries with high drug costs often pay close to the list price, or a percentage of it, during certain phases of their coverage. They were required to do so even though, in many cases, the companies operating the plans were collecting rebates on the same drug.

The rule had been opposed by the insurers and pharmacy benefit managers, who contended that they wielded the rebates to pressure drug companies to keep prices low, and used the savings to keep Medicare premiums low.

But the drug industry has been campaigning for years that it is unfair for insurers to keep the rebates when consumers are paying the list price through high deductibles.

Dems pan 'Zuck buck,' want Facebook to rein in currency plan

Dems pan 'Zuck buck,' want Facebook to rein in currency plan WASHINGTON (AP) — Facebook endured a second day of criticism from Congress over its plan to create a digital currency as senior House Democrats asked Facebook to scale back the project and threatened legislation that would block big tech companies from getting into banking. Facebook's massive market power and its record of scandals, fines and privacy breaches were on trial at a hearing Wednesday of the House Financial Services Committee. Lawmakers from both parties insisted they cannot trust the social network giant. "I think you're pretty low on the trust spectrum right now, and understandably," Rep.

Trump targets big pharma with new drug price executive order. Former Celgene CEO Bob Hugin on President Trump ' s efforts to rein in drug prices and “This is one way in which you can save and one way in which we can help middle-class families put more money back in their pockets,” RX Saver

If Trump were serious about lowering drug prices , he’d be asking for Democrats’ help to strengthen his ability to use that tool. That’ s how Doggett’ s bill works. An arbitration bill, by contrast, would provide a Democratic Party endorsement for Trump to tout a symbolic half-measure.

“At the end of the day, while we support the concept of getting rid of rebates and I am passionate about the problems and the distortions in system caused by this opaque rebate system, we are not going to put seniors at risk of their premiums going up,” Mr. Azar said.

He then tossed the ball to Congress, saying it could take up the rebate issue.

International Pricing Options

A pilot program announced last year has struck fear among drugmakers, who, like some Republicans in Congress, have described it as akin to foreign price controls. That project, unveiled in October, would tie the price of some drugs administered in medical offices like many cancer treatments to an international index of prices. The test program, under final review at the Office of Management and Budget, would last five years.

Senator Chuck Grassley of Iowa, the powerful Republican chairman of the Senate Finance Committee, denounced the idea last month, saying it could discourage research investments for new treatments. Conservative groups like Freedom Works and Americans for Tax Reform have been campaigning against the idea, too.

Even if Mr. Trump signs a broader executive order tying federal spending to overseas drug prices, it is not clear how much impact it would have. Most Americans are covered by commercial health insurance, which negotiates with drugmakers themselves. In many other countries with nationalized health care, the government is the negotiator.

The federal government buys drugs for small populations, like veterans and federal prisoners. Medicare’s prescription drug program farms out its purchasing to private companies and is barred from negotiating directly.

Trump’s Health Care Mission

Mr. Azar pleaded with reporters to “focus your energies” on a measure that will let employers provide money to workers to buy health insurance on their own, rather than enrolling in an employer-sponsored health plan.

And he pointed to an executive order Mr. Trump signed last month, intended to require insurance companies, doctors and hospitals to provide more transparent prices for medical care.

He also sought to play down the importance of the federal health law known as Obamacare.

“One of my frustrations is that the Affordable Care Act dominates so much of the discussion,” Mr. Azar said. “I’ve got to deliver affordable health care for 350 million Americans.”

He added, however, that the administration would provide “an ironclad protection for those who have pre-existing conditions” — the most popular of the health law’s consumer protections — no matter what happens with the court case.

Read More

7 modern lessons from the Apollo moon landing.
NASA faced a host of challenges -- politically, technologically, and financially -- as it sought to reach the moon in the 1960s. The strategies it employed can still inform space and other technology leaders today on how to pursue big goals and recover from the inevitable setbacks: What's your moon shot"? When President Kennedy set America on the course to the moon he sought a game-changing goal. Why? Because we were seemingly losing to the Russians in space and in the international political arena. To change the game, JFK changed the goal – to one that at the time seemed impossible.

—   Share news in the SOC. Networks

Topical videos:

usr: 4
This is interesting!